Cargando…

High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy

BACKGROUND: The high prevalence of type 2 diabetes mellitus (DM) among patients with colorectal cancer (CRC) is becoming a serious public health concern worldwide. FOLFOX4 chemotherapy is one of the most widely used adjuvant therapies in patients with stage III colon cancer after surgical resection....

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, I-Ping, Miao, Zhi-Feng, Huang, Ching-Wen, Tsai, Hsiang-Lin, Yeh, Yung-Sung, Su, Wei-Chih, Chang, Tsung-Kun, Chang, Se-fen, Wang, Jaw-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704420/ https://www.ncbi.nlm.nih.gov/pubmed/31467597 http://dx.doi.org/10.1177/1758835919866964

Ejemplares similares

Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy
por: Huang, Ching-Wen, et al.
Publicado: (2021)

Clinicopathological Features and Oncological Outcomes of Early and Late Recurrence in Stage III Colorectal Cancer Patients after Adjuvant Oxaliplatin-Based Therapy
por: Chang, Yu-Tang, et al.
Publicado: (2023)

Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer
por: Park, Dawon, et al.
Publicado: (2018)

Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial
por: Yeh, Yung-Sung, et al.
Publicado: (2017)

LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy
por: Lou, Yun-Ting, et al.
Publicado: (2015)

Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer
por: Huang, Chun-Ming, et al.
Publicado: (2017)

EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function
por: Huang, Ching-Wen, et al.
Publicado: (2017)

Metformin Enhancement of Therapeutic Effects of 5-Fluorouracil and Oxaliplatin in Colon Cancer Cells and Nude Mice
por: Yip, Kwan-Ling, et al.
Publicado: (2022)

Predictive Value of FOLFOX-Based Regimen, Long Interval, Hemoglobin Levels and Clinical Negative Nodal Status, and Postchemoradiotherapy CEA Levels for Pathological Complete Response in Patients with Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy
por: Huang, Chun-Ming, et al.
Publicado: (2020)

Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?
por: Tsai, Yi-Jian, et al.
Publicado: (2016)

Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4)
por: Chen, Chin-Fan, et al.
Publicado: (2008)

An observational study of extending FOLFOX chemotherapy, lengthening the interval between radiotherapy and surgery, and enhancing pathological complete response rates in rectal cancer patients following preoperative chemoradiotherapy
por: Huang, Chun-Ming, et al.
Publicado: (2016)

GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy
por: Lin, Wey-Ran, et al.
Publicado: (2016)

Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
por: Pectasides, Dimitrios, et al.
Publicado: (2015)

The Auxiliary Effects of Low-Molecular-Weight Fucoidan in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy Before Surgery: A Double-Blind, Randomized, Placebo-Controlled Study
por: Tsai, Hsiang-Lin, et al.
Publicado: (2023)

Sequential and co-occurring DNA damage response genetic mutations impact survival in stage III colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapy
por: Lin, Peng-Chan, et al.
Publicado: (2021)

Efficacy of concurrent radiotherapy in patients with locally advanced rectal cancer and synchronous metastasis receiving systemic therapy
por: Yin, Tzu-Chieh, et al.
Publicado: (2023)

Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX-4 chemotherapy
por: Han, Song-Hee, et al.
Publicado: (2019)

Epithelial-Mesenchymal Transition and MicroRNAs in Colorectal Cancer Chemoresistance to FOLFOX
por: Escalante, Paula I., et al.
Publicado: (2021)

Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis
por: Huang, Wen-Kuan, et al.
Publicado: (2021)

Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study
por: Le Roy, Bertrand, et al.
Publicado: (2016)

Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer: Where Are We at?
por: Yeh, Jen-Hao, et al.
Publicado: (2022)

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
por: Kwon, Yujin, et al.
Publicado: (2017)

Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer
por: Huang, Wen-Yen, et al.
Publicado: (2017)

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
por: André, Thierry, et al.
Publicado: (2013)

Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as secondline therapy for patients with advanced urothelial cancer
por: Zhang, Sheng, et al.
Publicado: (2016)

Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: A case report
por: Wang, Danping, et al.
Publicado: (2019)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Comparing efficacy and safety between Naldebain(®) and intravenous patient-controlled analgesia with fentanyl for pain management post-laparotomy: study protocol for a randomized controlled, non-inferior trial
por: Tsai, Hsiang-Lin, et al.
Publicado: (2019)

Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy
por: Kumamoto, Kensuke, et al.
Publicado: (2019)

High blood sugar levels significantly impact the prognosis of colorectal cancer patients through down-regulation of microRNA-16 by targeting Myb and VEGFR2
por: Yang, I-Ping, et al.
Publicado: (2016)

Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial
por: Ma, Cheng-Jen, et al.
Publicado: (2019)

Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer
por: Degirmencioglu, Serkan, et al.
Publicado: (2019)

MicroRNAs as Predictive Biomarkers in Patients with Colorectal Cancer Receiving Chemotherapy or Chemoradiotherapy: A Narrative Literature Review
por: Yang, I-Ping, et al.
Publicado: (2023)

A Prospective Study of Comparing Multi-Gene Biomarker Chip and Serum Carcinoembryonic Antigen in the Postoperative Surveillance for Patients with Stage I-III Colorectal Cancer
por: Chang, Yu-Tang, et al.
Publicado: (2016)

Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX
por: Kim, Mi-Jung, et al.
Publicado: (2016)

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
por: Qin, Shukui, et al.
Publicado: (2018)

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006)

Identification of LncRNAs Associated With FOLFOX Chemoresistance in mCRC and Construction of a Predictive Model
por: Zhang, Yiyi, et al.
Publicado: (2021)

ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
por: Baek, Moo-Jun
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bl34nic5aon5jan47nvqirsn68